Analysis of Adverse Event Summary
(Safety Analysis Population)

	Placebo		Xanomeline Low Dose		Xanomeline High Dose	
	n	(%)	n	(%)	n	(%)
Participants in population	86		84		84	
With any adverse event	69	(80.2)	77	(91.7)	79	(94.0)
With drug-related adverse event	44	(51.2)	73	(86.9)	70	(83.3)
With serious adverse event	0	(0.0)	1	(1.2)	2	(2.4)
With serious drug-related adverse event	0	(0.0)	1	(1.2)	1	(1.2)
Who died	2	(2.3)	1	(1.2)	0	(0.0)
Discontinued due to adverse event	0	(0.0)	0	(0.0)	0	(0.0)
Every subject is counted a single time for each applicable row and column.						

Source: ADSL and ADAE datasets